Drug Trial Radar · NCT05072080
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,258
Actual
Start
Sep 29, 2021
Primary completion
Apr 3, 2023
Study completion Apr 3, 2023
Sponsor
- Lead sponsor
- Bavarian NordicIndustry
- Sponsor type
- Industry
- Collaborators
- Emergent BioSolutions
- First posted
- Oct 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
Conditions
- Chikungunya Virus
Interventions
CHIKV VLP/adjuvantBiological
CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant 2%
PlaceboBiological
Placebo is comprised of formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Solicited Adverse Events (AE)Time frame: 7 days post-vaccination
- Incidence of Unsolicited AEsTime frame: 28 days post-vaccination
- Incidence of Adverse Events of Special Interest (AESI)Time frame: 182 days post-vaccination
- Incidence of Medically Attended Adverse Event (MAAE)Time frame: 182 days post-vaccination
- Incidence of Serious Adverse Event (SAE)Time frame: 182 days post-vaccination
- Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22Time frame: 21 days post-vaccination
- Anti-CHIKV Serum Neutralizing Antibody (SNA) Seroresponse Rates at Day 22 (Data Reported Per Arm)Time frame: 21 days post-vaccination
- Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22Time frame: 21 days post-vaccination
- Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - All Age Strata)Time frame: 21 days post-vaccination
- Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (for Lot Comparison)Time frame: 21 days post-vaccination
- Anti-CHIKV SNA Geometric Mean Titers (GMT) at Day 22 (Data Reported Per Arm - Adults 18 to <46)Time frame: 21 days post-vaccination
Locations
47 sites in 1 country. Site status is shown where the registry gives one.
Optimal Research, LLC
Huntsville, Alabama
Alliance for Multispecialty Research - Mobile
Mobile, Alabama
Alliance for Multispecialty Research, LLC
Tempe, Arizona
Velocity Clinical Research, Banning
Banning, California
Optimal Research, LLC
San Diego, California
Lynn Institute of the Rockies
Colorado Springs, Colorado
Jacksonville Center for Clinical Research
Jacksonville, Florida
Accel Research Sites-DeLand Clinical Research Unit
Lake Mary, Florida
Optimal Research, LLC
Melbourne, Florida
Suncoast Research Associates, LLC
Miami, Florida
Synexus Clinical Research US, Inc.
Pinellas Park, Florida
Palm Beach Research Center
West Palm Beach, Florida
Emory University School of Medicine
Atlanta, Georgia
Velocity Clinical Research, Boise
Meridian, Idaho
Synexus Clinical Research US, Inc.
Chicago, Illinois
Optimal Research LLC
Peoria, Illinois
Johnson County ClinTrials
Lenexa, Kansas
Alliance for Multispecialty Research, LLC
Newton, Kansas
Alliance for Multispecialty Research - Wichita East
Wichita, Kansas
Alliance for Multispecialty Research, LLC
Lexington, Kentucky
Alliance for Multispecialty Research, LLC
New Orleans, Louisiana
Optimal Research, LLC
Rockville, Maryland
Alliance for Multispecialty Research - Kansas City
Kansas City, Missouri
Saint Louis University
St Louis, Missouri
Synexus Clinical Research US, Inc.
St Louis, Missouri
Wr-Crcn, Llc
Las Vegas, Nevada
Alliance for Multispecialty Research, LLC.
Las Vegas, Nevada
Rochester Clinical Research, Inc.
Rochester, New York
M3 Wake Research, Inc
Raleigh, North Carolina
Trial Management Associates, LLC
Wilmington, North Carolina
Cincinnati Children's Hospital Medical Center - The Gamble Vaccine Research Center
Cincinnati, Ohio
Velocity Clinical Rsearch, Inc.
Cleveland, Ohio
Aventiv Research Inc.
Columbus, Ohio
Lynn Institute of Norman
Norman, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma
Velocity Clinical Research, Medford
Medford, Oregon
Velocity Clinical Research-Providence
East Greenwich, Rhode Island
Synexus Clinical Research US, Inc.
Anderson, South Carolina
Coastal Carolina Research Center
North Charleston, South Carolina
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.